Algeria will continue to use chloroquine therapeutic protocol

APS - 28 May 2020

ALGIERS- Algeria will continue the use of the therapeutic protocol based on hydroxychloroquine against the new coronavirus (COVID19), which has contributed "effectively" to the recovery of people suffering from this virus in Algeria, without any side effects, said Wednesday in Algiers Bekkat Berkani, member of the Scientific Committee in charge of monitoring the evolution of the Covid-19 pandemic.

In a statement to the APS, Bekkat, also president of the National Council of the Algerian Medical Association, said that Algeria will continue the use, against the new coronavirus, of the therapeutic protocol based on chloroquine, which has not caused any side effects to patients undergoing this treatment to date."

He stressed in this context that the use of this protocol in the treatment of the new coronavirus in Algeria "is carried out in a scientific framework, with careful monitoring of patients even after their recovery.

This statement comes in the wake of the controversy recently raised following the publication by the World Health Organization (WHO) of recommendations calling for the suspension of the use of chloroquine in the treatment of coronavirus patients.

This decision follows the publication of a study in the medical journal "The Lancet" which found that the use of chloroquine against Covid-19 is ineffective or even harmful.

For Bekkat, the information published by this journal is "ambiguous" and sows "doubt" about the link of certain international lobbies and laboratories with this information. It is an attempt to put pressure for the marketing of drugs more expensive than chloroquine, at an affordable price."

"Algeria refuses to engage in this kind of conflict, and will continue the use of this protocol for people diagnosed positive for the virus", based on the principle of "making the general interest of citizens prevail", especially since its use "is a real success and it proves its effectiveness day by day," he said.

In the same context, Berkani said that the said study is based mainly on the possible risks of this drug, in extreme cases, whose cure rate is very low, which explains the deaths recorded in this context, while Algeria uses Chloroquine for diagnosed cases and not only for critical cases.